Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.

Autor: Vassal G; Department of Clinical Research, Institut Gustave Roussy, Paris-Sud University, Paris, France. Electronic address: gvassal@igr.fr., Rousseau R; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: rousseau.raphael@gene.com., Blanc P; Imagine for Margo, 9 Avenue Eric Tabarly, 78112 Fourqueux, France. Electronic address: imagineformargo@gmail.com., Moreno L; CNIO Centro Nacional de Investigaciones Oncológicas, C/ Melchor Fernández Almagro, 3, E-28029 Madrid, Spain. Electronic address: lmorenom@cnio.es., Bode G; International Confederation of Childhood Cancer Parent Organizations, Schouwstede 2B, 3431 JB Nieuwegein, The Netherlands. Electronic address: gerlind-bode@t-online.de., Schwoch S; Eli Lilly, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK. Electronic address: schwoch_stefan@lilly.com., Schrappe M; Department of General Pediatrics, Christian-Albrechts-University and Medical Centre Schleswig-Holstein, Campus Kiel, Schwanenweg 20, D-24105 Kiel, Germany. Electronic address: m.schrappe@pediatrics.uni-kiel.de., Skolnik J; GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 19112, USA. Electronic address: jeffrey.m.skolnik@gsk.com., Bergman L; Medizinische Klinik II, J.W. Goethe Universität, D-60590 Frankfurt, Germany. Electronic address: l.bergmann@em.uni-frankfurt.de., Bradley-Garelik MB; Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA. Electronic address: m.brigid.bradleygarelik@bms.com., Saha V; Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, 550 Wilmslow Rd, Manchester M20 4BX, UK. Electronic address: vaskar.saha@manchester.ac.uk., Pearson A; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, London SM2 5NG, UK. Electronic address: Andrew.Pearson@icr.ac.uk., Zwierzina H; Medizinische Universität Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. Electronic address: heinz.zwierzina@i-med.ac.at.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2015 Jan; Vol. 51 (2), pp. 218-24. Date of Electronic Publication: 2014 Nov 27.
DOI: 10.1016/j.ejca.2014.10.029
Abstrakt: Seven years after the launch of the European Paediatric Medicine Regulation, limited progress in paediatric oncology drug development remains a major concern amongst stakeholders - academics, industry, regulatory authorities, parents, patients and caregivers. Restricted increases in early phase paediatric oncology trials, legal requirements and regulatory pressure to propose early Paediatric Investigation Plans (PIPs), missed opportunities to explore new drugs potentially relevant for paediatric malignancies, lack of innovative trial designs and no new incentives to develop drugs against specific paediatric targets are some unmet needs. Better access to new anti-cancer drugs for paediatric clinical studies and improved collaboration between stakeholders are essential. The Cancer Drug Development Forum (CDDF), previously Biotherapy Development Association (BDA), with Innovative Therapy for Children with Cancer Consortium (ITCC), European Society for Paediatric Oncology (SIOPE) and European Network for Cancer Research in Children and Adolescents (ENCCA) has created a unique Paediatric Oncology Platform, involving multiple stakeholders and the European Union (EU) Commission, with an urgent remit to improve paediatric oncology drug development. The Paediatric Oncology Platform proposes to recommend immediate changes in the implementation of the Regulation and set the framework for its 2017 revision; initiatives to incentivise drug development against specific paediatric oncology targets, and repositioning of drugs not developed in adults. Underpinning these changes is a strategy for mechanism of action and biology driven selection and prioritisation of potential paediatric indications rather than the current process based on adult cancer indications. Pre-competitive research and drug prioritisation, early portfolio evaluation, cross-industry cooperation and multi-compound/sponsor trials are being explored, from which guidance for innovative trial designs will be provided.
(Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: